Monitor CRB-701 + pembrolizumab 1L OPSCC data in Q1 2027 and interim ORR readout in 2L OPSCC in 1H 2028 as key value inflection points. CRB-913 additional Phase 1b data at ObesityWeek November 2026 will be the next near-term catalyst.
Price Chart
Executive Summary
Corbus Pharmaceuticals filed an 8-K furnishing an updated corporate presentation. The presentation highlights Phase 1/2 data for CRB-701 (Nectin-4 ADC) showing a 42.9% confirmed ORR at 3.6 mg/kg in 2L OPSCC and 34.4% ORR in 2L cervical cancer, and Phase 1b data for CRB-913 (CB1 inverse agonist for obesity) showing 5% placebo-adjusted weight loss at 12 weeks with a favorable safety profile. Key upcoming catalysts include CRB-701 + pembrolizumab data in 1L OPSCC in Q1 2027 and initiation of a Phase 2 monotherapy study for CRB-913 in 1H 2027.
Key Facts
- CRB-701 at 3.6 mg/kg Q3W showed 42.9% confirmed ORR and 85.7% DCR in 2L OPSCC (n=21) with median DoR of 6.3 months and median PFS of 5.6 months.
- CRB-701 at 3.6 mg/kg showed 34.4% confirmed ORR and 75.0% DCR in 2L cervical cancer (n=32) with median DoR of 8.0 months and median PFS of 4.3 months.
- CRB-913 (60mg) showed 5% placebo-adjusted average weight loss at 12 weeks with no plateauing; 12.9% AE-related discontinuation rate.
- Registrational TEMPO-1 study in 2L OPSCC (CRB-701 vs investigator's choice, N≈250) commenced in September 2026.
- CRB-701 + pembrolizumab data in 1L OPSCC expected Q1 2027; potential BLA filing in 2L OPSCC in 2H 2028.
- CRB-913 Phase 2 monotherapy study (CANYON-2) expected to start 1H 2027.
- Cash, cash equivalents & investments of $118M as of June 30, 2026; ~18.7M common shares outstanding (~22.4M fully diluted).
Financial Impact
No new financial guidance or material financial data provided; cash position of $118M disclosed as of June 30, 2026.
Risk Factors
- CRB-701 efficacy is concentrated in HPV+ OPSCC subset; non-OPSCC HNSCC showed 0% ORR at 3.6 mg/kg, limiting addressable population.
- CRB-913 is early-stage (Phase 1b); Phase 2 data may not replicate weight loss or safety profile.
- Cash runway of $118M may require additional financing before potential BLA filing in 2H 2028.
- Competitive landscape includes Padcev (enfortumab vedotin) already in NCCN guidelines for HNSCC and established GLP-1 obesity therapies.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-422437 |
| Document: crbp-20261015.htm | 0001193125-26-422437 |
| Document: 0001193125-26-422437-index-headers.html | 0001193125-26-422437 |
| Document: 0001193125-26-422437-index.html | 0001193125-26-422437 |
| Document: 0001193125-26-422437.txt | 0001193125-26-422437 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $4.33 | awaiting T+60 | — | $3.99 (−7.85%) |
Sep 30, 2026 27d ago | SC 13G | $6.34 | awaiting T+60 | — | $3.99 (−37.07%) |
Sep 22, 2026 5w ago | Institutional Cluster | $7.88 | awaiting T+60 | — | $3.99 (−49.33%) |
Sep 14, 2026 6w ago | 8-K | $8.08 | awaiting T+60 | — | $3.99 (−50.62%) |
Sep 11, 2026 6w ago | Press Release | $8.08 | awaiting T+60 | — | $3.99 (−50.62%) |
Aug 12, 2026 10w ago | Insider Cluster | $10.08 | awaiting T+60 | — | $3.99 (−60.42%) |
Aug 10, 2026 11w ago | Insider Cluster | $9.51 | awaiting T+60 | — | $3.99 (−58.04%) |
May 26, 2026 22w ago | 8-K | $7.91 $9.99 | ▲ +26.30% | ▲ +23.57% | $3.99 (−49.56%) |
May 21, 2026 22w ago | 8-K | $11.51 $10.49 | ▼ −8.86% | ▼ −13.16% | $3.99 (−65.33%) |
May 14, 2026 23w ago | 8-K | $11.98 $9.46 | ▼ −21.04% | ▼ −24.62% | $3.99 (−66.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers